3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
European Medical Solutions's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 99.79%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for European Medical Solutions's 3-Year ROIIC % or its related term are showing as below:
STU:AS00's 3-Year ROIIC % is ranked better than 78.14% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs STU:AS00: 99.79
European Medical Solutions (STU:AS00) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
European Medical Solutions 3-Year ROIIC % Related Terms
European Medical Solutions 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AS00 vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, European Medical Solutions's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 2.588612 (Dec. 2025) - -1.64967 (Dec. 2022) )
/
( 32.494 (Dec. 2025) - 28.247 (Dec. 2022) )
=
4.238282
/
4.247
=
99.79%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
European Medical Solutions (STU:AS00) has a 3-Year ROIIC % of 99.79 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on European Medical Solutions and its competitors. This is 134% above median its historical median of 42.59. According to the industry distribution chart, European Medical Solutions ranks #289 out of 1322 companies in the Biotechnology industry, placing it in the top 21.9%.
Is European Medical Solutions' 3-Year ROIIC % too high?
European Medical Solutions' current 3-Year ROIIC % of 99.79 is 134% above median its 10-year median of 42.59. Based on the distribution chart, European Medical Solutions ranks #289 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, European Medical Solutions has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, European Medical Solutions ranks #289 out of 1322 companies for 3-Year ROIIC %. This places European Medical Solutions in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on European Medical Solutions and its competitors. European Medical Solutions's current 3-Year ROIIC % is 99.79, which is 134% above median its own 10-year median of 42.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current 3-Year ROIIC % of 99.79. The stock's GF Value™ is €8.16, compared to a current price of €3.98 — trading 51.2% below its estimated fair value. The current 3-Year ROIIC % is 99.79, which is 134% above median its 10-year median of 42.59. European Medical Solutions' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current 3-Year ROIIC % is 99.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €3.98 is trading 51.2% below its estimated GF Value™ of €8.16.
Key valuation signals for STU:AS00:
3-Year ROIIC %: 99.79 (134% above median its 10-year median of 42.59)
GF Value™: €8.16 vs. price of €3.98 (51.2% below fair value)
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
43GF Score
Get the complete analysis for STU:AS00
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
